The UK and US have reached a significant commercial pact that will guarantee zero duties on British medicine products being sold in the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to increase funding on medicines through the NHS. This commitment guarantees that import taxes on these crucial exports will be held at zero for a timeframe of the next three years.
This deal is in response to previous threats to significantly raise import taxes on patented pharmaceutical products, with increases discussed up to double the cost.
"This deal with the United Kingdom strengthens the international landscape for cutting-edge drugs and introduces much-needed fairness to U.S.–U.K. pharmaceutical trade," a release declared.
Commercial Importance
Drugs are one of the UK's largest goods shipped to the US, which is easily the largest destination for major British pharmaceutical firms.
Export figures reveal that in the year prior to September, the UK exported drugs valued at £11.1bn to the US. This amount represented nearly one-fifth of total UK exports in that period.
"This agreement protects employment, increases investment and facilitates the UK to become a international leader for biotech and pharma," the Business and Trade Secretary stated.
Specific British Pledges
The deal involves several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it deems new treatments to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a goal to double total health service expenditure on medicines from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The sum pharmaceutical firms must pay back to the NHS to prevent overspending will be limited at fifteen percent. In the past, rebates were more than 20%.
Broader Context
The pact follows a long-running tension between the drug companies and the UK government over medicine costs and regulatory access.
The disagreement were heightened by arguments that American consumers were charged several times more for the same drugs than people in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been delayed or abandoned, while substantial funding commitments have been pledged toward US facilities.
One official publicly accepted that the NHS had to increase expenditure on treatments, noting that its expenditure on drugs had declined as a proportion of its total funding over the last ten years.
